Press release
Janus Kinase (JAK) Inhibitors Market Trends, Top Companies, Share, Growth And Forecast 2032
Janus Kinase (JAK) Inhibitors Market
The Business Research Company's Janus Kinase (JAK) InhibitorsGlobal Market Report 2023 identifies the increase in instances of autoimmune diseases as the major driver for the janus kinase (JAK) inhibitors market's growth in the forecast period. Autoimmune diseases are a broad group of disorders characterized by an abnormal immune response in which the immune system mistakenly attacks and damages healthy cells, tissues, and organs. Janus Kinase (JAK) inhibitors provide therapeutic benefits for autoimmune diseases by modulating the immune system, reducing inflammation, and alleviating symptoms such as rheumatoid arthritis.
The global Janus Kinase (JAK) inhibitors market is expected to grow from $14.61 billion in 2022 to $17.29 billion in 2023 at a compound annual growth rate (CAGR) of 18.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The Janus Kinase (JAK) inhibitors market is expected to reach $33.38 billion in 2027 at a CAGR of 17.9%.
Download Free Sample Of Janus Kinase (JAK) InhibitorsMarket Report - https://www.thebusinessresearchcompany.com/sample_request?id=12467&type=smp
Major competitors in the janus kinase (JAK) inhibitors market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., GSK Plc., Takeda Pharmaceutical Company Ltd., Eli Lilly and Co., Gilead Sciences Inc., Boehringer Ingelheim Group, Teva Pharmaceutical Industries Ltd.
A key trend in the janus kinase (JAK) inhibitors market includes product innovation. Major companies operating in the Janus kinase (JAK) inhibitors market are focused on innovating technologically advanced solutions to sustain their position in the market. For instance, in May 2022, Eli Lilly and Company, a US-based pharmaceutical company, and Incyte, a Switzerland-based biopharmaceutical company, announced the approval of OLUMIANT (baricitinib) by the U.S. Food and Drug Administration (FDA). It is the first and only JAK inhibitor FDA-approved for treating COVID-19 in some hospitalized individuals who need varying levels of oxygen assistance. OLUMIANT is approved for treating adult hospital patients with extracorporeal membrane oxygenation (ECMO), non-invasive or invasive mechanical breathing, or COVID-19 disease 2019 (COVID-19).
Read More On The Global Janus Kinase (JAK) InhibitorsMarket Report Here:
https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report
The janus kinase (JAK) inhibitors market is segmented -
• By Inhibitors Type: Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib, Other Inhibitor Types
• By Mode Of Administration: Injectable, Oral, Other Modes Of Administration
• By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies
• By Application: Autoimmune Disorders, Oncology, Inflammatory Disorders, Metabolic Disorders
• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the janus kinase (JAK) inhibitors market.
The Business Research Company's "Global Janus Kinase (JAK) InhibitorsMarket Report 2023" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.
Explore Buying Options For The Janus Kinase (JAK) InhibitorsMarket Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12467
The Table Of Content For The Janus Kinase (JAK) InhibitorsMarket Include:
1. Executive Summary
2. Janus Kinase (JAK) InhibitorsMarket Characteristics
3. Janus Kinase (JAK) InhibitorsMarket Trends And Strategies
4. Janus Kinase (JAK) InhibitorsMarket - Macro Economic Scenario
5.1. Global Janus Kinase (JAK) InhibitorsHistoric Market Size and Growth, 2017 - 2022, Value ($ Billion)
……
32. Global Janus Kinase (JAK) InhibitorsMarket Competitive Benchmarking
33. Global Janus Kinase (JAK) InhibitorsMarket Competitive Dashboard
34. Key Mergers And Acquisitions In The Janus Kinase (JAK) InhibitorsMarket
35. Janus Kinase (JAK) InhibitorsMarket Future Outlook and Potential Analysis
36. Appendix
Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx
Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.
Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Janus Kinase (JAK) Inhibitors Market Trends, Top Companies, Share, Growth And Forecast 2032 here
News-ID: 3258551 • Views: …
More Releases from The Business research company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for JAK
Key Trends Influencing the Growth of the Janus Kinase (JAK) Inhibitors Market in …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Janus Kinase (JAK) Inhibitors Market Through 2025?
The market size of Janus Kinase (JAK) inhibitors has experienced a quick growth over the recent years. The market, which stood at $20.19 billion in 2024, is projected to see a rise to $23.56 billion…
Vitiligo Treatment Innovation Accelerates with JAK Inhibitors and Novel Immunoth …
Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving the Vitiligo treatment landscape. Let's explore how this will impact the Vitiligo treatment landscape.
DelveInsight's "Vitiligo Pipeline Insight, 2025 [https://www.delveinsight.com/report-store/vitiligo-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights on the vitiligo pipeline, showcasing a dynamic landscape of emerging therapies and a promising outlook for patients suffering from this challenging autoimmune skin…
Global Jak And Pi3k Signaling Pathway Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Jak And Pi3k Signaling Pathway market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The JAK and PI3K signaling pathway market is experiencing significant growth due to the increasing…
Leading Growth Driver in the Janus Kinase (JAK) Inhibitors Market in 2025: Surgi …
Which drivers are expected to have the greatest impact on the over the janus kinase (jak) inhibitors market's growth?
The escalating occurrences of autoimmune disorders are anticipated to stimulate the expansion of the Janus kinase (JAK) inhibitors market. These disorders involve a broad spectrum of abnormalities within the immune system where it erroneously attacks and destroys healthy cells, tissues, and organs. The therapeutic benefits of Janus Kinase (JAK) inhibitors for autoimmune…
Janus Kinase (JAK) Inhibitor Pipeline Therapeutics Assessment Report 2024 (Updat …
DelveInsight's, "Janus Kinase Inhibitor Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Janus Kinase…
Janus kinase (JAK) Inhibitors Competitive Landscape Report 2024
DelveInsight's, "Janus kinase inhibitors Competitive landscape 2024" report provides comprehensive insights about 40+ Janus kinase Inhibitors Companies and 45+ drugs in Janus kinase inhibitors Competitive landscape. It covers the Janus kinase Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Janus kinase Inhibitors Report
• DelveInsight's Janus kinase Inhibitors report depicts a robust space…
